Sutro Biopharma (FRA:S090) Moat Score: 5/10 (As of Jul. 13, 2026)


FRA:S090 Sutro Biopharma Inc FRA:S090
50 GF Score
Price €25.20
GF Value €9.87
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Moat Score?

Sutro Biopharma FRA:S090 -6.67% 50 Moat Score is 5 as of Jul. 13, 2026. GuruFocus rates FRA:S090 with a GF Score™ of 50/100 and a GF Value™ of €9.87 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,396 Biotechnology companies, Sutro Biopharma ranks better than 96.7% on this metric.

Sutro Biopharma has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Sutro Biopharma has Narrow Moat: Sutro Biopharma Inc has valuable intellectual property and patents in the biopharmaceutical industry. While it shows solid R&D capabilities, the competitive landscape and lack of significant customer switching costs limit its moat to a solid narrow level.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sutro Biopharma might have Narrow Moat - Solid narrow moat.

Sutro Biopharma  (FRA:S090) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sutro Biopharma Moat Score Related Terms

FRA:S090 vs NGNE, OCGN, CBIO: Moat Score Comparison

For the Biotechnology subindustry, Sutro Biopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sutro Biopharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Moat Score falls into.


FRA:S090
50GF Score
Sutro Biopharma Inc FRA:S090
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Sutro Biopharma (FRA:S090) has a Moat Score of 5 as of Jul. 13, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sutro Biopharma ranks #46 out of 1396 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Sutro Biopharma's Moat Score too high?
Sutro Biopharma's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Sutro Biopharma's value of 5 is 150% above this industry median. Based on the distribution chart, Sutro Biopharma ranks #46 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sutro Biopharma has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Moat Score compare to NGNE and OCGN?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #46 out of 1396 companies for Moat Score. This places Sutro Biopharma in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Sutro Biopharma's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sutro Biopharma's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sutro Biopharma's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (FRA:S090) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.87, compared to a current price of €25.20 — trading 155.3% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Sutro Biopharma's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sutro Biopharma (FRA:S090), the current Moat Score is 5 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sutro Biopharma (FRA:S090) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of €25.20 is trading 155.3% above its estimated GF Value™ of €9.87. GuruFocus considers Sutro Biopharma to be Significantly Overvalued.

Key valuation signals for FRA:S090:

  • Moat Score: 5
  • GF Value™: €9.87 vs. price of €25.20 (155.3% above fair value)
  • GF Score™: 50/100 with 4 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1396)

No single metric tells the full story. See the FRA:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges STRO:USA
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
50GF Score

Get the complete analysis for FRA:S090

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€25.20
Price
€9.87
GF Value